ChiCTR2500105376 版本V1.0 版本创建时间2025/07/02 15:33:29 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500105376 

最近更新日期:

Date of Last Refreshed on:

2025-07-02 15:33:13 

注册时间:

Date of Registration:

2025-07-02 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

新生儿高胆红素脑病的诊断技术与药物研究

Public title:

Diagnostic techniques and drug research for neonatal hyperbilirubinemic encephalopathy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

新生儿高胆红素脑病的诊断技术与药物研究

Scientific title:

Diagnostic techniques and drug research for neonatal hyperbilirubinemic encephalopathy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

万芊 

研究负责人:

时海波 

Applicant:

Wan Qian 

Study leader:

Shi Haibo 

申请注册联系人电话:

Applicant telephone:

+86 150 5027 0112

研究负责人电话:

Study leader's telephone:

+86 189 3017 7657

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lily-f1870816@sjtu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

haibo99@hotmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市徐汇区宜山路600号

研究负责人通讯地址:

上海市徐汇区宜山路600号

Applicant address:

No. 600 Yishan Road, Xuhui District, Shanghai, China

Study leader's address:

No. 600 Yishan Road, Xuhui District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市第六人民医院

Applicant's institution:

Shanghai Sixth People's Hospital

研究负责人所在单位:

上海市第六人民医院

Affiliation of the Leader:

Shanghai Sixth People's Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024-138

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海市第六人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Shanghai Sixth People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-07-30 00:00:00

伦理委员会联系人:

贾伟平

Contact Name of the ethic committee:

Jia Weiping

伦理委员会联系地址:

上海市第六人民医院

Contact Address of the ethic committee:

Shanghai Sixth People's Hospital

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 64369181

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市第六人民医院

Primary sponsor:

Shanghai Sixth People's Hospital

研究实施负责(组长)单位地址:

上海市徐汇区宜山路600号

Primary sponsor's address:

No. 600 Yishan Road, Xuhui District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

上海

Country:

China

Province:

Shanghai

City:

Shanghai

单位(医院):

上海市第六人民医院

具体地址:

上海市徐汇区宜山路600号

Institution
hospital:

Shanghai Sixth People's Hospital

Address:

No. 600 Yishan Road, Xuhui District, Shanghai, China

经费或物资来源:

院级项目

Source(s) of funding:

Hospital-level project

Target disease:

neonatal hyperbilirubinemic encephalopathy

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

1.建立敏感、高效的新生儿黄疸所致中枢损害的超早期诊断技术体系; 2.创新研发有效拮抗胆红素神经毒性作用的靶向性治疗药物。  

Objectives of Study:

1.Establish a sensitive and efficient ultra-early diagnostic technology system for central nervous system damage caused by neonatal jaundice. 2.Innovate and develop targeted therapeutic drugs to effectively antagonize the neurotoxic effects of bilirubin.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.近三年入住新生儿病房并顺利出院的28日龄以内新生儿; 2.住院期间留有血液生化检测结果; 3.住院期间完成听力筛查并留有听力筛查结果; 4.住院期间完成行为学评估。

Inclusion criteria

1. Neonates within 28 days of life who were admitted to the neonatal ward in the past three years and were successfully discharged; 2. Had blood biochemical test results available during hospitalization; 3. Completed hearing screening with results available during hospitalization; 4. Had behavioral assessments performed during hospitalization.

排除标准:

1.超早产儿(胎龄小于28周); 2.过期产儿(胎龄大于42周); 3.产钳助产及严重分娩损伤儿(如骨折、臂丛神经损伤); 4.宫内感染儿; 5.重度胎儿窘迫儿及有其它明确原因导致神经系统损伤儿。

Exclusion criteria:

1. Extremely preterm infants (gestational age < 28 weeks); 2. Post-term infants (gestational age > 42 weeks); 3. Infants delivered with forceps assistance and/or sustaining severe birth injuries(e.g., fractures, brachial plexus injury); 4. Infants with intrauterine infections; 5. Infants with severe fetal distress and/or neurological damage from other confirmed causes.

研究实施时间:

Study execute time:

From 2025-01-01 00:00:00 To 2027-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-01-01 00:00:00 To 2026-12-31 00:00:00  

干预措施:

Interventions:

组别:

Case series

样本量:

600

Group:

Case series

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

上海市第六人民医院 

单位级别:

三甲 

Institution
hospital:

Shanghai Sixth People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

复旦大学附属儿科医院 

单位级别:

三甲 

Institution
hospital:

Fudan University Affiliated Children's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

上海交通大学医学院附属儿童医院 

单位级别:

三甲 

Institution
hospital:

Shanghai jiaotong University Affiliated Children's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

胆红素

指标类型:

主要指标

Outcome:

Bilirubin

Type:

Primary indicator

测量时间点:

出生早期新生儿胆红素连续7天

测量方法:

Measure time point of outcome:

Daily bilirubin levels during the first 7 days of life in newborns

Measure method:

指标中文名:

与胆红素水平相关的血尿指标

指标类型:

主要指标

Outcome:

Blood and urine biomarkers associated with bilirubin levels,

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

头颅核磁共振

指标类型:

次要指标

Outcome:

MRI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑电图

指标类型:

次要指标

Outcome:

EEG

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

听觉脑干诱发电位

指标类型:

次要指标

Outcome:

BAEP

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 0 years
最大 Max age 1 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机

Randomization Procedure (please state who generates the random number sequence and by what method):

Non-randomized.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究公开发表后半年,邮件联系研究负责人合理获取。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Six months after the publication of the research, contact the research leader via email to obtain reasonable information.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集为病历记录表,数据管理为统一的电子信息表管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data collection is the record table of the medical records, and the data management is the unified electronic information table management.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-07-02 15:33:13